Re reading the announcement and the HC posts suggests this time it is not another false start.
Furthermore teeing up with Astra Zenica is not too shabby either. I have interests in a few biotechs which have been developing slowly due to various reasons including lead times and phase 1/2/3 issues, but it is their market caps predominantly that binds them.
PAB is in another league altogether.
I look forward to being on board with you all and doing a little more reading.
Ann: PAT-DX1 is synergistic with PARP inhibitor, page-7
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $14.40M | |||
| Open | High | Low | Value | Volume |
| 0.7¢ | 0.7¢ | 0.7¢ | $11.67K | 1.667M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1024077 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 1520772 | 4 |
View Market Depth
| Last trade - 14.28pm 13/09/2024 (20 minute delay) ? |
| PAB (ASX) Chart |